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OBJECTIVE — Although subjects with diabetes have increased risk for cardiovascular
disease (CVD), the evolution of this increased risk as pre-diabetic individuals progress to
diabetes is not understood. This study examines the longitudinal relationship between
selected CVD risk factors (blood pressure, triglycerides, HDL and LDL cholesterol, and LDL
peak particle density [PPD]) and glycemia in the three treatment groups of the Diabetes
Prevention Program.
RESEARCH DESIGN AND METHODS — A total of 3,234 participants with impaired
glucose tolerance (IGT) were followed for a mean of 3.2 years after randomization to
intensivelifestyleintervention(ILS),metformin,orplacebo.Usingrepeated-measuresmod-
els, adjusted mean levels of risk factors were estimated for an annual change in glycemic
status. Tests were also conducted to assess the risk factor trends with improvement or
worsening of glycemic status.
RESULTS — CVD risk factor values and changes from baseline became more unfavorable as
glucose tolerance status deteriorated but improved with reversion to normal glucose tolerance
(NGT), especially in the ILS intervention group (trend test P  0.001 for all risk factors except
forLDLPPD[P0.02]inILSandHDLcholesterol[P0.02]inplacebo).Althoughtherewere
few signiﬁcant differences in the transition from IGT to diabetes, there were strong relationships
between risk factors and continuous measures of glycemia.
CONCLUSIONS — Progression from IGT to diabetes is associated with mild deterioration,
whereasreversiontoNGTisassociatedwithimprovementinriskfactors.Earlyinterventionwith
ILS, but less so with metformin, in participants at high risk for diabetes improves the cardiovas-
cular risk and glucose tolerance proﬁle simultaneously.
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C
ardiovascular disease (CVD) is the
major cause of morbidity and mor-
tality in diabetes (1). Although the
excess risk for CVD in diabetes has been
linked to a clustering of risk factors that
include blood pressure and lipoprotein
abnormalities (2), little is known about
the evolution of this risk as pre-diabetic
individuals progress toward diabetes. An
adverse pattern of CVD risk factors is al-
ready present in normoglycemic subjects
who subsequently develop diabetes com-
paredwiththosewhodonot(3),suggest-
ing that factors other than worsening
hyperglycemia are responsible for the or-
igins of the increased cardiovascular risk
in diabetes. However, no studies have
prospectively evaluated the effects of de-
terioration of glycemia on CVD risk fac-
tors in pre-diabetic subjects in whom
CVD incidence appears to be somewhat
increased (4). The opportunity to exam-
ine this issue was made possible by the
Diabetes Prevention Program (DPP),
which studied the development of diabe-
tes in a large population with impaired
glucose tolerance (IGT) and in which in-
tensive lifestyle (ILS) or metformin inter-
ventions were compared with placebo
(5).
RESEARCH DESIGN AND
METHODS— This report includes
3,234 participants in the ILS, metformin,
and placebo treatment arms. Individuals
were recruited from a variety of sources
based on the risk for development of dia-
betes (5). Written informed consent was
obtained from all participants before
screening, consistent with the Helsinki
Declaration and the guidelines of each
center’s institutional review board. Eligi-
bility was based on results of a 75-g oral
glucose tolerance test (OGTT). Inclusion
criteria included a fasting plasma glucose
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for American Indians) and a 2-h plasma
glucose of 7.8–11.1 mmol/l following the
glucose load, age 25 years, and BMI
24 kg/m
2 (22 kg/m
2 for Asian Amer-
icans).Majorexclusionsincludedarecent
myocardial infarction, symptoms of coro-
nary heart disease, major illness, prior di-
agnosis of diabetes, or use of medications
known to impair glucose tolerance.
Eligible participants were randomly
assigned to one of three interventions:
850 mg metformin twice daily (MET
group), placebo twice daily (placebo
group), or an intensive program of life-
style modiﬁcation (ILS group). Random
treatment assignments were stratiﬁed ac-
cording to clinical center and double
blinded for the MET and placebo groups.
The goals of the ILS were to achieve and
maintainaweightreductionofatleast7%
of initial body weight through consump-
tion of a low-calorie, low-fat diet and to
engageinmoderatephysicalactivityforat
least 150 min/week (5).
Diabetes was diagnosed on the basis
of an annual OGTT or a semiannual fast-
ing plasma glucose test according to
AmericanDiabetesAssociation(ADA)cri-
teria (6). The diagnosis required conﬁr-
mation by a second test, usually within 6
weeks. Glycated hemoglobin, systolic
(SBP) and diastolic blood pressure (DBP),
triglycerides, HDL cholesterol, LDL cho-
lesterol, and LDL peak particle density
(PPD) (7–10) were assessed annually.
Statistical analysis
Study design and analysis were con-
ductedaccordingtotheintention-to-treat
principle. Participants were followed for
anaverageof3.2years,aperiod4months
longer than that reported previously
when participants and staff still remained
unmasked to study results (5). Compari-
sonsamonggroupsatbaselineweremade




for multiple comparisons. Results of the
OGTT were used to designate a partici-
pant’s glucose tolerance status as normal
glucosetolerance(NGT),IGT,ordiabetes
by ADA criteria (6). Mean levels of CVD
riskfactorsatannualvisitswereestimated
according to OGTT status and treatment
groupunderﬁxed-effectsmodelswiththe
assumptionofnormallydistributederrors
(11). Adjustment was made for baseline
risk factor levels, demographics, time
from randomization, and medications in-
ﬂuencing the risk factor level under a re-
peated-measures model with a ﬁrst-order
autoregressive(AR1)covariancestructure
to account for within-individual variabil-
ity; in some analyses, BMI, waist circum-
ference,orhomeostasismodelassessment
of insulin resistance (HOMA-IR) were in-
cluded in the model.
To obtain maximal power to evaluate
whether a change in OGTT status was ac-
companied by a change in risk factor lev-
els, all OGTT results between any two
consecutive annual visits were examined,
yielding ﬁve interval patterns. These
ranged from an improvement (IGT 3
NGT), through lack of change in those
who had achieved NGT (NGT), or re-
mained with IGT (IGT 3 IGT), to deteri-
oration from an achieved normal to
impaired(NGT3IGT),andfromnormal
or impaired to diabetes (NGT/IGT 3
DM) status; the last two categories were
combined due to small numbers in the
NGT-to-diabetes category. Fixed-effects
models with time-varying covariates and
assumptionofnormallydistributederrors
(11) were used to estimate the adjusted
mean change in risk factor levels for a
change in glucose tolerance status at
1-year intervals. When available, the risk
factor level at the time of diabetes diagno-
sis was used. Otherwise, the next avail-
able risk factor levels following diagnosis
were used (47 in the placebo group, 29 in
the ILS group, and 37 in the MET group)
with an average time of 0.5–0.6 years
from diagnosis. Excluding these intervals
from the individuals did not affect the
analysis, so they have been included. The
analyses excluded intervals after diabetes
Table 1—Baseline demographic, clinical, and laboratory characteristics by treatment group
Overall Placebo Metformin Lifestyle P
n 3,234 1,082 1,073 1,079
Age (years) 50.6  10.7 50.3  10.4 50.9  10.3 50.6  11.3 0.45
Sex 0.35
Male 1,043 (32.3) 335 (31.0) 363 (33.8) 345 (32.0)
Female 2,191 (67.7) 747 (69.0) 710 (66.2) 734 (68.0)
Race/ethnicity 0.49
Caucasian 1,768 (54.7) 586 (54.2) 602 (56.1) 580 (53.8)
African American 645 (19.9) 220 (20.3) 221 (20.6) 204 (18.9)
Hispanic 508 (15.7) 168 (15.5) 162 (15.1) 178 (16.5)
American Indian 171 (5.3) 59 (5.5) 52 (4.8) 60 (5.6)
Asian American 142 (4.4) 49 (4.5) 36 (3.4) 57 (5.3)
Fasting glucose (mmol/l) 5.9  0.5 5.9  0.5 5.9  0.5 5.9  0.4 0.45
2 h glucose (mmol/l) 9.1  0.9 9.1  1.0 9.2  1.0 9.1  0.9 0.56
A1C (%) 5.9  0.50 5.9  0.5 5.9  0.5 5.9  0.5 1.00
SBP (mmHg) 123.7  14.7 123.5  14.4 124.0  14.9 123.7  14.8 0.66
DBP (mmHg) 78.3  9.3 78.0  9.2 78.3  9.5 78.6  9.2 0.33
Triglycerides (mmol/l) 1.85  1.08 1.91  1.13 1.79  1.02 1.84  1.10 0.05
Total cholesterol (mmol/l) 5.26  0.94 5.25  0.95 5.25  0.92 5.28  0.95 0.67
LDL cholesterol (mmol/l) 3.23  0.85 3.21  0.87 3.23  0.84 3.24  0.85 0.76
HDL cholesterol (mmol/l) 1.18  0.31 1.16  0.30 1.19  0.30 1.19  0.32 0.01
LDL size (Rf  1,000) 264.4  29.6 262.7  31.1 265.6  28.7 264.8  29.0 0.06
Data are n (%) or means  SD. RF, relative ﬂotation.
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veloped diabetes at mid-year visits dur-
ing the last 6 months of the study. The
trend test was used to test the associa-
tion between the changes in glucose tol-
erance categories and the risk factor
levels using the same ﬁxed-effects mod-
els described above but with categories
coded 1 through 5. Changes in risk fac-
tor levels were also described as percent
of the baseline SD to allow for compar-
ison among the different distributions
of risk factors.
RESULTS— Table 1 shows baseline
characteristics, which did not differ
among treatment groups except for HDL
cholesterol and triglycerides. Table 2
summarizes mean risk factor levels ac-
cording to annual OGTT status by treat-
ment group. Among the three treatment
groups, HDL cholesterol, triglyceride,
and LDL-PPD values differed by OGTT
status (P  0.02) as did SBP and DBP for
the ILS and placebo groups. Point esti-
mates showed more favorable risk factor
levels with NGT compared with diabetes,
with the IGT values being intermediate;
speciﬁcally, triglycerides, LDL-PPD, and
HDL cholesterol were signiﬁcantly differ-
ent in those with NGT versus those with
IGT or diabetes, with only occasional dif-
ferences in those with IGT versus diabe-
tes. In the state of NGT, there were
differences among treatments in all CVD
risk factors (P  0.001), with the most
favorable values noted in the ILS group.
These treatment group differences per-
sisted in the IGT state, except for LDL
cholesterol, but were mostly absent in
those with diabetes.
Figure 1 summarizes mean changes
in risk factors ordered according to the
OGTT interval patterns. Overall, deteri-
oration of glucose tolerance was associ-
ated with a worsening of risk factor
levels, whereas improvement in status
wasassociatedwithabeneﬁcialriskfac-
torchange.Thetrendtestsperformedto
assess relationships between the change
in ordered categories of glucose toler-
ance and changes in CVD risk factors
were statistically signiﬁcant (P  0.001
for all risk factors except for LDL-PPD
[P  0.02]intheILSgroupandforHDL
cholesterol [P  0.02] in the placebo
group.
Table 2—Adjusted mean levels (95% CI) of cardiovascular risk factor by glucose tolerance status and treatment group at annual visits*
OGTT status P for
OGTT status
P for
interaction† NGT IGT Diabetes
SBP (mmHg)
ILS group 119.0 (118.2–119.7) 121.2 (120.4–121.9) 123.6 (121.5–125.8) 0.001 0.04
MET group 122.1 (121.3–123.0) 123.0 (122.3–123.7) 122.9 (121.4–124.3) 0.17
Placebo group 121.9 (121.0–122.8) 123.1 (122.3–123.8) 124.5 (123.1–125.8) 0.003
P value for treatment 0.001 0.001 0.29
DBP (mmHg)
ILS group 74.0 (73.5–74.5) 74.9 (74.4–75.4) 77.2 (75.7–78.7) 0.001 0.001
MET group 77.0 (76.4–77.6) 76.9 (76.5–77.4) 76.4 (75.4–77.4) 0.55
Placebo group 76.4 (75.8–77.0) 76.8 (76.4–77.3) 78.6 (77.7–79.5) 0.001
P value for treatment 0.001 0.001 0.004
Triglycerides (mmol/l)
ILS group 1.46 (1.42–1.51) 1.64 (1.59–1.68) 1.73 (1.62–1.85) 0.001 0.68
MET group 1.65 (1.60–1.70) 1.79 (1.74–1.84) 1.85 (1.73–1.96) 0.001
Placebo group 1.59 (1.53–1.65) 1.80 (1.75–1.86) 1.86 (1.78–1.95) 0.001
P value for treatment 0.001 0.001 0.20
LDL cholesterol
(mmol/l)
ILS group 3.11 (3.07–3.15) 3.15 (3.12–3.19) 3.12 (3.04–3.20) 0.13 0.23
MET group 3.13 (3.09–3.17) 3.15 (3.11–3.18) 3.11 (3.04–3.18) 0.48
Placebo group 3.21 (3.17–3.26) 3.19 (3.15–3.23) 3.12 (3.06–3.18) 0.05
P value for treatment 0.001 0.21 0.98
HDL cholesterol
(mmol/l)
ILS group 1.22 (1.21–1.23) 1.20 (1.19–1.21) 1.18 (1.15–1.20) 0.002 0.81
MET group 1.20 (1.19–1.22) 1.19 (1.18–1.20) 1.17 (1.15–1.19) 0.02
Placebo group 1.19 (1.18–1.20) 1.17 (1.16–1.18) 1.15 (1.13–1.16) 0.001
P value for treatment 0.001 0.001 0.08
LDL-PPD (Rf  1,000)
ILS group 272 (271–273) 268 (266–269) 263 (260–266) 0.001 0.58
MET group 267 (266–269) 265 (263–266) 260 (257–263) 0.001
Placebo group 267 (265–268) 264 (262–265) 261 (259–263) 0.001
P value for treatment 0.001 0.001 0.35
*MeansandCIswereobtainedfromﬁxed-effectsmodels,withanautoregressivecovariancestructuretoaccountforwithin-personvariabilityandfurtheradjustment
for baseline age, sex, race/ethnicity, year of assessment, baseline CVD risk factor, and any medications that may affect the CVD risk factor. P values represent
comparisonsamongtreatmentgroupsforeachglucosetolerancecategoryandviceversa.†ThePvalueforinteractionindicateswhethertheeffectoftheOGTTstatus
differs by treatment group. RF, relative ﬂotation.
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The largest changes are seen for transi-
tionsfromIGTtoNGTintheILSgroup,
where SBP and triglyceride fell by
25%, whereas HDL cholesterol and
LDL-PPD increased by 8 and 17% of
the baseline SD, respectively. The MET
and placebo groups showed less signif-
icant improvements.
Unchanged glucose tolerance status
For IGT, risk factors showed little or no
interval change across treatment groups,
whereas for NGT, risk factor means im-
proved slightly, mainly in ILS group, in
which SBP, DBP, and triglyceride levels
fell(P0.01)by7,9,and7%ofbaseline
SD, respectively, while HDL cholesterol
and LDL-PPD increased (P  0.05) by 5
and 6% of baseline SD, respectively.
Worsening glucose tolerance status
Deterioration from NGT to IGT over 1
year manifested a slight increase in trig-
lycerides for the ILS and placebo groups
(P  0.05). The mean HDL cholesterol
change decreased slightly in the MET and
placebo groups (P  0.05), while LDL
cholesterol slightly increased in the ILS
group (P  0.05).
Conversion to diabetes
Progression from IGT to diabetes in the
ILSgroupwasnotassociatedwithanysig-
niﬁcant change in risk factors. DBP in-
creased in the placebo group by 1.0
mmHg (P  0.04) but decreased in the
MET group by 1.2 mmHg (P  0.04),
while HDL cholesterol and LDL-PPD fell
in the placebo and MET groups (P 
0.05) and LDL cholesterol fell in the pla-
cebo group (P  0.02).
Figure 2 expresses the mean risk fac-
tor change in relation to interval changes
in fasting and 2-h glucose, BMI, and
HOMA-IR in quartiles to assess relation-
Figure 1—Mean interval change in cardiovascular risk factors by category of glucose tolerance interval change and by treatment group. The mean
intervalchangeswiththeirﬁve95%conﬁdencelimitsforSBP,DBP,triglycerides,HDLcholesterol,LDLcholesterol,andLDL-PPDarearrangedfrom
left to right in each panel by treatment group, according to whether there was improvement in glucose tolerance status (IGT to NGT), maintenance
of improvement (NGT to NGT), no change (IGT to IGT), deterioration back to baseline status (NGT to IGT), or conversion to diabetes (DM)
(IGT/NGT to diabetes). E, ILS group; f, MET group; ‚, placebo group.
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measures of glycemia and to evaluate the
extent to which BMI and HOMA-IR con-
tributedtoriskfactorchange.OverallSBP
and triglyceride levels increased, and
HDL cholesterol and LDL-PPD values de-
creased in the three intervention groups
asafunctionofeachmeasureofglycemia,
BMI, and HOMA-IR. Fasting glucose
tended to correlate less well with risk fac-
tor levels than did 2-h glucose or A1C. In
mixed models, BMI and waist interval
changes explained the effect of glycemia
on SBP, and BMI only explained effects
for LDL-PPD and attenuated those on
HDL cholesterol, whereas HOMA-IR
changes were found to have no inﬂuence.
CONCLUSIONS — This study shows
that participants who developed diabetes
trended toward higher blood pressure
and triglycerides and lower HDL choles-
terol and LDL-PPD levels than those who
remained with IGT, while those whose
OGTT reverted to normal had a signiﬁ-
cantly more favorable proﬁle. These ﬁnd-
ings demonstrate that small changes in
glycemia have a measurable effect on car-
diometabolic risk factors in subjects with
IGT, although no such tendency was
noted for LDL cholesterol, as previously
noted (3). When risk factor changes were
assessed over 1-year intervals in relation
to OGTT status, favorable effects were
again noted among those with improving
glucose tolerance, while unfavorable
trends accompanied deteriorating glu-
cose tolerance.
Based upon differences in absolute
risk factor levels as well as annual interval
changesinthosewithIGTversusdiabetes
the incremental risk associated with pro-
gression to diabetes is modest. Using ep-
idemiologic predictors of coronary heart
disease risk, a reduction in HDL choles-
terol of 0.02 mmol/l (0.78 mg/dl) and an
elevation in SBP of 2 mmHg would pre-
dictanincreaseineventratesof1.5–2.0%
and2–3%ineventsover10years,respec-
tively (12,13). However, we found that
risk factor values were associated with
glycemic measures expressed as continu-
ous variables, indicating that there is no
unique effect of conversion to diabetes
but rather a linear relationship between
glycemic measures and risk factor levels,
as previously noted in cross-sectional
studies (14). We found that quartiles of
fasting glucose did not correlate as well
with risk factors as did the 2-h glucose
levels. This may reﬂect the narrow range
of fasting glucose levels in our partici-
pants, although fasting glucose values
may not correlate as well with CVD risk
factors and events as do 2-h glucose val-
ues (4).
While there appeared to be little dif-
ference in risk factors between interven-
tion groups in those who developed
diabetes, for participants who remained
with IGT or NGT, the risk factor proﬁle
among those in the ILS group was more
favorable than the MET and placebo
groups. Since fewer participants devel-
oped diabetes and more reverted to NGT




time (15) is at least partially linked to the
pattern of glucose tolerance responses to
the interventions. The similarity of the
riskfactorproﬁlesinparticipantswhode-
veloped diabetes in the three groups
Figure2—Meancardiovascularriskfactorintervalchangesadjustedforage,sex,andbaselineriskfactorvaluesbyquartilesofchangeinmeasures
of glycemia and by treatment groups at 1-year intervals. The symbols and horizontal black line denote the mean change and 95% CI in selected
cardiovascular risk factors for the three treatment groups: E, ILS group; f, MET group; ‚, placebo group. The numbers on the symbols correspond
to the quartile of change in each of the measures of glycemia at 1-year intervals. The trend test across quartiles of glycemia showed a signiﬁcant
association (all P  0.01) with SBP, triglycerides, HDL cholesterol, and LDL-PPD (except fasting glucose).
Glucose tolerance changes and cardiovascular risk factors
730 DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009couldalsoreﬂectalackofsuccesswiththe
active interventions.
In the course of the DPP, 1,921 indi-
viduals reverted to NGT (39% in the ILS
group and 23% in the placebo group).
Reversion from IGT to NGT was associ-
ated with reductions in SBP, DBP, and
triglyceridesandincreasesinHDLcholes-
terolandLDL-PPD.Thiseffectwassignif-
icantly greater in the ILS group, where, in
addition, LDL cholesterol levels fell and
the estimated reduction in risk of heart
disease predicted from epidemiologic as-
sessments is 10–13% (12,13,16). This
couldagainbepartlyexplainedbyamore
sizable improvement in glucose tolerance
in the ILS group. Alternatively, other rel-
evant effects of lifestyle change, such as
weight reduction, increased physical ac-
tivity, dietary changes, or improved insu-
linsensitivityweremoresubstantialinthe
ILS group than the other groups (5) and
should be greatest in those reverting to
NGT. Furthermore, where participants
maintained NGT for at least a year, there
were further beneﬁcial changes in risk
factorlevels,particularlyintheILSgroup,
whereas worsening from NGT to IGT was
associated with a signiﬁcant deterioration
in the risk proﬁle. These ﬁndings suggest
that reversion to NGT from IGT is associ-
ated with long-term improvement in risk
factor status, which deteriorates rapidly if
glucosetoleranceworsens.Previousstud-
ies (17,18) have highlighted the impor-
tance of insulin resistance and weight
change on CVD risk factors. This analysis
indicates that BMI, but not insulin resis-
tance, explains a signiﬁcant proportion of
the inﬂuence of glycemia on cardiometa-
bolic risk, obliterating its effect on blood
pressure and LDL-PPD but not on HDL
cholesterol and triglycerides. This supports
the concept that the increased cardiometa-
bolic risk that accompanies deteriorating
glucose tolerance likely reﬂects combined
effects of elevated glucose levels and in-
creasing weight, which are closely interre-
lated. In addition, the importance of these
ﬁndings relates not only to future risk of
CVD but also to the likelihood of the devel-
opment of diabetes itself, since CVD risk
factors were found to predict development
of diabetes in pre-diabetic subjects inde-
pendent of glycemic status (19).
Insummary,thisanalysisdemonstrates
that progression from IGT to diabetes is
associated with a small deterioration in
the CVD risk factor proﬁle in a manner
that reﬂects a continuous relationship
with glycemia and is independent of ILS
or metformin interventions. These ﬁnd-
ings indicate that biochemical conversion
to diabetes from pre-diabetes has limited
signiﬁcance for CVD complications of di-
abetes, although sizable changes in glyce-
mia may have greater effects (20).
Together with longer duration of diabe-
tes, this may explain why typically the
risk factor proﬁle is more unfavorable in
subjects with diabetes than those with IGT
(14). Importantly, improvement of glucose
tolerance is associated with a more favor-
able risk factor proﬁle, with ILS accompa-
nied by larger improvements than
metformin. Although the changes in CVD
risk factors during the short period of fol-
low-up in this study were small, they occur
on a background of increased CVD risk
(21), and their determinants may over time
lead to a more substantial deterioration of
cardiovascular risk in diabetic subjects.
Theythereforerepresentatargetforpreven-
tion of CVD at an early phase in the devel-
opment of diabetes.
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